# A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

> **NCT03847909** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 35 (actual)

## Conditions studied

- Primary Hyperoxaluria Type 1 (PH1)
- Primary Hyperoxaluria Type 2 (PH2)
- Kidney Diseases
- Urologic Diseases
- Genetic Disease

## Interventions

- **DRUG:** DCR-PHXC
- **DRUG:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT03847909
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-28
- **Primary completion:** 2021-06-21
- **Final completion:** 2021-06-29
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03847909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03847909, "A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03847909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*